

Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Jeremy Carlier**

Work experience

08/2018 - present

Researcher

Sezione di Medicina Legale, Dipartimento Scienze Anatomiche, Istologiche, Medico Legali e dell'Apparato Locomotore, Sapienza Università di Roma (Italy)

Project design: Metabolite profiling of Novel Psychoactive Substances in human

Writing of literature review articles in forensic toxicology

Review and English proofreading of scientific manuscripts (articles and book chapters)

Teaching courses in forensic toxicology

03/2017 – 04/2018

Lab Supervisor and Technical Supervisor

CIAN Diagnostics (MD, USA)

Staff management: 4 engineers, 4 lab assistants, 2 administrative assistants

Quality Assessment management (ISO/IEC 17025)

Analytical equipment management and Technology watch

Purchasing management (instruments and consumables)

Development of LC-MS/MS methods for quantifying drugs of abuse, Novel Psychoactive Substances, opioids, opioid antagonists, benzodiazepines, amphetamines, and barbiturates in urine and oral fluid

Interpretation of analytical results and writing of toxicology reports

12/2014 – 02/2017

Postdoctoral Researcher

Chemistry and Drug Metabolism Section, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) (MD, USA)

Instrument supervision (troubleshooting, staff training, and maintenance):

LC-HRMS/MS Q Exactive and Q Exactive Plus (Thermo Scientific)

Project management: Metabolite profiling of Novel Psychoactive Substances in human

- In silico predictions of metabolite profile
- Human liver microsome and human hepatocyte incubations with NPS
- Extraction methods development in urine
- LC-HRMS/MS methods development for detecting metabolites in incubations and urine
- Metabolite identification with data-mining software
- Acquisition of authentic specimens via international collaborations

Development of an LC-MS/MS method for quantifying AM-2201 (synthetic cannabinoid) in human and rat plasma

Pharmacokinetic and pharmacodynamic profiling of AM-2201 and metabolites in rats

05/2010 – 11/2014

Graduate Researcher

LAT LUMTOX (France)

Involvement in the lab accreditation (ISO/IEC 17025)
 Instrument supervision (troubleshooting, staff training, and maintenance):
 LC-HRMS/MS Q Exactive (Thermo Scientific)
 Project management: Analytical characterization of intoxications by phytotoxins

- Toxin purification from plant extracts
- NMR analysis of purified extracts
- Development of GC-MS, LC-MS/MS, and LC-HRMS/MS methods (targeted methods and targeted screenings) for detecting and quantifying phytotoxins in humans (blood, urine, hair, bile, liver, and kidney)
- Acquisition of authentic specimens via international collaborations

Development of an LC-HRMS/MS untargeted toxicological screening
 Development of LC-MS/MS and LC-HRMS/MS targeted methods for detecting and quantifying opioids and anticonvulsants in humans (blood and urine)
 Routine tests with GC-MS, LC-MSn, LC-MS/MS, and LC-HRMS/MS

01/2009 – 09/2009

Undergraduate Researcher

Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire Raymond Poincaré (France)

Development of LC-MS/MS methods for quantifying psychotropic drugs in hair and drugs of abuse in blood

Education and training

2014

Ph.D. Analytical Chemistry and Forensic Toxicology

Lyon 1 University in collaboration with LAT LUMTOX (France)

Dissertation: "Forensic implication of plant-origin toxins: Analytical approach"

2009

M.Sc. Biochemistry – Biomedical Engineering; Chemical and biological analyses

Paris 5 University (France)

Dissertation: "Contribution of hair testing in paleopathology research: Development and validation of an LC-MS/MS method for quantifying the most widespread, naturally occurring, psychotropic drugs; case reports"

2007

B.Sc. Biology – Sciences, Technologies, Health; Human biology and health

Title of qualification awarded

Paris 11 University (France)

Personal skills and competences

Mother tongue(s)

French

Other language(s)

English, Italian

Self-assessment

European level

Language

Language

		Understanding		Speaking				Writing	
		Listening	Reading	Spoken interaction		Spoken production			
E	C1		C1		C1		C1		C1
I	A2		A2		A2		A2		A1

Publications

35) Di Trana A, **Carlier J**, Berretta P, Zaami S, and Ricci G. *Consequences of COVID-19 lockdown on the misuse and marketing of addictive substances and New Psychoactive Substances*. Front Psychiatry, 2020; 11: 584462 (DOI: 10.3389/fpsyt.2020.584462).

34) Brunetti P, Lo Faro AF, Tini A, Busardò FP, and **Carlier J**. *Pharmacology of herbal sexual enhancers: A systematic review of psychiatric and neurological adverse effects*. Pharmaceuticals, 2020; 13 (10): E309 (DOI: 10.3390/ph13100309).

- 33) Brunetti P, Pirani F, **Carlier J**, Giorgetti R, Busardò FP, and Lo Faro AF. *A 2017-2019 update on acute intoxications and fatalities from illicit fentanyl and analogues*. J Anal Toxicol, 2020; Accepted (DOI: 10.1093/jat/bkaa115).
- 32) Malaca S, **Carlier J**, and Busardò FP. *Advances in forensic toxicology*. Curr Pharm Des, 2020; 26 (31): 3779-3780 (DOI: 10.2174/138161282631200810123637).
- 31) Malaca S, **Carlier J**, Pichini S, and Busardò FP. *Measurement uncertainty in forensic toxicology*. Ther Drug Monit, 2020; 42 (4): 653-654 (DOI: 10.1097/FTD.0000000000000775).
- 30) Pichini S, **Carlier J**, Di Trana A, Malaca S, Giorgetti R, and Busardò FP. *Unity is strength*. TIAFT Bull, 2020; 50 (1): 26-30.
- 29) Di Trana A†, La Maida N†, Tittarelli R, Huestis MA, Pichini S, Busardò FP, and **Carlier J**. *Monitoring prenatal exposure to buprenorphine and methadone*. Ther Drug Monit, 2020; 42 (4): 181-193 (DOI: 10.1097/FTD.0000000000000693).
- 28) **Carlier J**, La Maida N, Di Trana A, Huestis MA, Pichini S, and Busardò FP. *Testing unconventional matrices to monitor for prenatal exposure to heroin, cocaine, amphetamines, synthetic cathinones, and synthetic opioids*. Ther Drug Monit, 2020; 42 (2): 205-221 (DOI: 10.1097/FTD.0000000000000719).
- 27) **Carlier J**, Huestis MA, Zaami S, Pichini S, and Busardò FP. *Monitoring the effects of perinatal cannabis and synthetic cannabinoid exposure*. Ther Drug Monit, 2020; 42 (2): 194-204 (DOI: 10.1097/FTD.0000000000000667).
- 26) Busardò FP, Vari MR, Di Trana A, Malaca S, **Carlier J**, and Di Luca NM. *Drug-facilitated sexual assaults (DFSA): A serious underestimated issue*. Eur Rev Med Pharmacol Sci, 2019; 23 (24): 10577-10587 (DOI: 10.26355/eurrev_201912_19753).
- 25) Huestis MA, Solimini R, Pichini S, **Carlier J**, Pacifici R, and Busardò FP. *Cannabidiol adverse effects and toxicity*. Curr Neuropharmacol, 2019; 17 (10): 974-989 (DOI: 10.2174/1570159X17666190603171901).
- 24) Busardò FP, **Carlier J**, Giorgetti R, Pacifici R, Gottardi M, and Pichini S. *Ultra-high-performance liquid chromatography-tandem mass spectrometry assay for quantifying fentanyl and 22 analogs and metabolites in whole blood, urine, and hair*. Front Chem, 2019; 7: 184 (DOI: 10.3389/fchem.2019.00184).
- 23) **Carlier J**, Giorgetti R, Vari MR, Pirani F, Ricci G, and Busardò FP. *Use of cognitive enhancers: Methylphenidate and analogs*. Eur Rev Med Pharmacol Sci, 2019; 23 (1): 3-15 (DOI: 10.26355/eurrev_201901_16741).
- 22) **Carlier J**, Wohlfarth A, Salmeron BD, Scheidweiler KB, Huestis MA, and Baumann MH. *Pharmacodynamic effects, pharmacokinetics, and metabolism of the synthetic cannabinoid AM-2201 in male rats*. J Pharmacol Exp Ther, 2018; 367 (3): 543-550 (DOI: 10.1124/jpet.118.250530).
- 21) **Carlier J†**, Diao X†, and Huestis MA. *Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection*. J Pharm Biomed Anal, 2018; 157: 27-35 (DOI: 10.1016/j.jpba.2018.05.007).
- 20) Diao X, **Carlier J**, Zhu M, and Huestis MA. *Human hepatocyte metabolism of new synthetic cannabinoid EG-018 by high-resolution mass spectrometry*. Forensic Toxicol, 2018; 36 (2): 304-312 (DOI: 10.1007/s11419-018-0404-2).
- 19) Diao X†, **Carlier J†**, Zhu M, and Huestis MA. *Human hepatocyte metabolism of two novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18*. Clin Chem, 2017; 63 (11): 1753-1763 (DOI: 10.1373/clinchem.2017.277152).
- 18) **Carlier J**, Diao X, Wohlfarth A, Scheidweiler KB, and Huestis MA. *In vitro metabolite profiling of ADB-FUBINACA, a new synthetic cannabinoid*. Curr Neuropharmacol, 2017; 15 (5): 682-691 (DOI: 10.2174/1570159X15666161108123419).

- 17) **Carlier J**, Diao X, Scheidweiler KB, and Huestis MA. *Distinguishing intake of new synthetic cannabinoids, ADB-PINACA and 5F-ADB-PINACA, with human hepatocyte metabolites and high resolution mass spectrometry*. Clin Chem, 2017; 63 (5): 1008-1021 (DOI: 10.1373/clinchem.2016.267575).
- 16) Wohlfarth A, Roman M, Andersson M, Kugelberg F, Diao X, **Carlier J**, Huestis MA, and Kronstrand R. *25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry*. Drug Test Anal, 2017; 9 (5): 680-698 (DOI: 10.1002/dta.2044).
- 15) **Carlier J†**, Diao X†, Sempio C, and Huestis MA. *Identification of new synthetic cannabinoid ADB-CHMINACA (MAB-CHMINACA) metabolites in human hepatocytes*. AAPS J, 2017; 19 (2): 568-577 (DOI: 10.1208/s12248-016-0037-5).
- 14) Diao X†, **Carlier J†**, Scheidweiler KB, and Huestis MA. *In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry*. Forensic Toxicol, 2017; 35 (2): 252-262 (DOI: 10.1007/s11419-016-0350-9).
- 13) Diao X, **Carlier J**, Zhu M, Pang S, Wohlfarth A, Kronstrand R, Scheidweiler KB, and Huestis MA. *In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)*. Forensic Toxicol, 2017; 35 (1): 20-32 (DOI: 10.1007/s11419-016-0326-9).
- 12) **Carlier J**, Scheidweiler KB, Wohlfarth A, Salmeron B, Baumann MH, and Huestis MA. *Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry*. J Chromatogr A, 2016; 1451: 97-106 (DOI: 10.1016/j.chroma.2016.05.020).
- 11) Swortwood MJ†, **Carlier J†**, Ellefsen KN, Wohlfarth A, Diao X, Concheiro-Guisan M, Kronstrand R, and Huestis MA. *In vitro, in vivo, and in silico metabolic profiling of α -pyrrolidinopentiothiophenone, a novel thiophene stimulant*. Bioanalysis, 2016; 8 (1): 65-82 (DOI: 10.4155/bio.15.237).
- 10) Mazoyer C, **Carlier J**, Sastre C, and Di Fazio V. *Synthetic cannabinoids: Analytical methods*. Toxicol Anal Clin, 2015; 27 (3): 184-194 (DOI: 10.1016/j.toxac.2015.03.112).
- 9) Boemer F, Deberg M, Schoos R, Baise E, Amory H, Gault G, **Carlier J**, Gaillard Y, Marcillaud-Pitef C, and Votion D. *Quantification of hypoglycin A in serum using aTRAQ® assay*. J Chromatogr B Analyt Technol Biomed Life Sci, 2015; 997: 75-80 (DOI: 10.1016/j.jchromb.2015.06.004).
- 8) **Carlier J**, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L, Habyarimana J, Gault G, and Gaillard Y. *A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS*. J Chromatogr B Analyt Technol Biomed Life Sci, 2015; 978-979: 70-77 (DOI: 10.1016/j.jchromb.2014.11.029).
- 7) **Carlier J**, Guitton J, Romeuf L, Bévalot F, Boyer B, Fanton L, and Gaillard Y. *Screening approach by ultra-high performance liquid chromatography-tandem mass spectrometry for the blood quantification of thirty-four toxic principles of plant origin. Application to forensic toxicology*. J Chromatogr B Analyt Technol Biomed Life Sci, 2015; 975: 65-76 (DOI: 10.1016/j.jchromb.2014.10.028).
- 6) **Carlier J**, Romeuf L, Guitton J, Priez-Barallon C, Bévalot F, Fanton L, and Gaillard Y. *A validated method for quantifying atractyloside and carboxyatractyloside in blood by HPLC-HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L*. J Anal Toxicol, 2014; 38 (9): 619-627 (DOI: 10.1093/jat/bku078).
- 5) **Carlier J**, Guitton J, Bévalot F, Fanton L, and Gaillard Y. *The principal toxic glycosidic steroids in Cerbera manghas L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC-HRMS/MS, quantification by UHPLC-PDA-MS*. J Chromatogr B Analyt Technol Biomed Life Sci, 2014; 962: 1-8 (DOI: 10.1016/j.jchromb.2014.05.014).

- 4) **Carlier J**, Escard E, Péoc'h M, Boyer B, Romeuf L, Faict T, Guitton J, and Gaillard Y. *Atropine eye drops: An unusual homicidal poisoning*. J Forensic Sci, 2014; 59 (3): 859-864 (DOI: 10.1111/1556-4029.12412).
- 3) Priez-Barallon C, **Carlier J**, Boyer B, Benslima M, Fanton L, Mazoyer C, and Gaillard Y. *Quantification of pregabalin using Hydrophilic Interaction HPLC-High Resolution MS in post-mortem human samples: Eighteen case reports*. J Anal Toxicol, 2014; 38 (3): 143-148 (DOI: 10.1093/jat/bku004).
- 2) Mazoyer C, **Carlier J**, Boucher A, Péoc'h M, Lemeur C, and Gaillard Y. *Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and post-mortem biological material*. J Forensic Sci, 2013; 58 (6): 1666-1672 (DOI: 10.1111/1556-4029.12250).
- 1) Gaillard Y, **Carlier J**, Berscht M, Mazoyer C, Bévalot F, Guitton J, and Fanton L. *Fatal intoxication due to ackee (Blighia sapida) in Suriname and French Guyana. GC-MS detection and quantification of hypoglycin-A*. Forensic Sci Int, 2011; 206 (1-3): 103-107 (DOI: 10.1016/j.forsciint.2011.01.018).

†The authors equally contributed to the manuscript

Presentations

- 21) **Carlier J**, Diao X, and Huestis MA. *Identification des métabolites de BB-22 dans des incubations d'hépatocytes humains*. [Oral presentation]. 26th Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the *Swiss Centre de Compétences en Chimie et Toxicologie Analytique* (ccCTA), Marseille (France), 2018
- 19) and 20) **Carlier J**, Diao X, Wohlfarth A, Scheidweiler KB, and Huestis MA. *In vitro metabolite profiling of ADB-FUBINACA, a new synthetic cannabinoid*. [Oral presentation]. National Institute on Drug Abuse fellows research lunch, Baltimore, MD (USA), March 25, 2016; and also at the 24th Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA), Perpignan (France), 2016.
- 18) Swortwood MJ, **Carlier J**, Ellefsen KN, Wohlfarth A, Kronstrand R, and Huestis MA. *Metabolic profiling of α -PVT, a novel stimulant thiophenyl analog*. [Oral presentation]. 46th Annual Meeting of the Society of Forensic Toxicologists (SOFT), Atlanta, GA (USA), 2015.
- 17) Habyarimana J, Boemer F, Amory H, Baise E, **Carlier J**, De Tullio P, Douny C, Gault G, Gustin P, Fanck T, Frederich M, Marcillaud-Pitel C, Richard E, Patarin F, Weber M, and Votion D. [Oral presentation]. *Les nouveaux outils de diagnostic et de pronostic de la myopathie atypique*. Proceedings of the 41st day of equine research, Paris (France), 2015.
- 15) and 16) **Carlier J**, Moreau C, Guitton J, Bévalot F, Boyer B, Fanton L, and Gaillard Y. *A validated method for quantifying hypoglycin A in blood by UHPLC-HRMS/MS*. [Oral presentation]. 22nd Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the Toxicological Society of Belgium and Luxembourg (BLT) and the *Swiss Centre de Compétences en Chimie et Toxicologie Analytique* (ccCTA), Bordeaux (France), 2014; and also at the 52nd Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Buenos Aires (Argentina), 2014.
- 13) and 14) **Carlier J**, Romeuf L, Guitton J, Bévalot F, Boyer B, Fanton L, and Gaillard Y. *A validated method for quantifying atractyloside and carboxyatractyloside in blood and urine by HPLC-HRMS/MS, a non-fatal case of intoxication with Atractylis gummifera L.* [Oral presentation]. 22nd Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the Toxicological Society of Belgium and Luxembourg (BLT) and the *Swiss Centre de Compétences en Chimie et Toxicologie Analytique* (ccCTA), Bordeaux (France), 2014; and also at the 52nd Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Buenos Aires (Argentina), 2014.
- 12) **Carlier J**, Moreau C, Romeuf L, Boyer B, and Gaillard Y. *A validated method for quantifying fifteen fentanyl derivatives in blood by UHPLC-MS/MS*. [Poster]. 52nd Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Buenos Aires (Argentina), 2014.

- 11) **Habyarimana J**, Baise E, Weber M, Fanck T, Gault G, **Carlier J**, Votion D, and Gustin P. [Poster]. *Validation of a HPTLC method for quantitative determination of hypoglycin A in methanol extracts of maple (Acer) samples*. International Symposium for High-Performance Thin-Layer Chromatography (HPTLC), Lyon (France), 2014.
- 10) **Carlier J**, Guitton J, Bévalot F, Fanton L, and Gaillard Y. *Blood screening by UHPLC-HRMS of fifty-five natural compounds of toxicological interest*. [Poster]. 51st Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Madeira (Portugal), 2013.
- 9) **Carlier J**, Guitton J, Bévalot F, Fanton L, and Gaillard Y. *The principal glycosidic steroids in Cerbera manghas L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC-HRMS/MS, quantification by UHPLC-PDA/MS*. [Poster]. 51st Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Madeira (Portugal), 2013.
- 8) **Priez-Barallon C**, **Carlier J**, Boyer B, Benslimma M, Fanton L, and Gaillard Y. *Quantification of pregabalin by high-resolution HILIC-MS in post-mortem samples: Regarding 16 cases*. [Poster]. 51st Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Madeira (Portugal), 2013.
- 7) **Carlier J**, Guitton J, Bévalot F, Fanton L, and Gaillard Y. *Criblage par CLUHP-SM à haute résolution dans le sang, de cinquante-deux composés d'origine naturelle d'intérêt toxicologique*. [Oral presentation]. 21st Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the *Société de Toxicologie Clinique* (STC), Saint-Malo (France), 2013.
- 5) and 6) **Carlier J**, Guitton J, Bévalot F, Fanton L, and Gaillard Y. *Quantification de la cerbérine, la nériifoline (déacétylcerbérine), la tanghinine et la déacétyltanghinine par CLUHP-BPD/SM dans les graines du Cerbera manghas L. Confirmation par CLUHP-SM² haute résolution*. [Oral presentation during the Young Scientists Symposium and Poster]. 21st Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the *Société de Toxicologie Clinique* (STC), Saint-Malo (France), 2013.
- 4) **Carlier J**, Mazoyer C, Boyer B, Benslimma M, Fanton L, Priez-Barallon C, and Gaillard Y. *Quantification de la prégabaline par CLUH-SM à haute résolution dans des prélèvements post-mortem : A propos de seize cas*. [Poster]. 21st Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA) in association with the *Société de Toxicologie Clinique* (STC), Saint-Malo (France), 2013.
- 3) **Carlier J**, Escard E, Péoc'h M, Boyer B, Romeuf L, Faict T, and Gaillard Y. *Atropine eye drops: An unusual homicidal poisoning*. [Poster]. 50th Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Hamamatsu (Japan), 2012.
- 2) Mazoyer C, Capobianco C, Boucher A, **Carlier J**, Romeuf L, Priez-Barallon C, Maurer HH, and Gaillard Y. *Case report of a 25-year-old woman death under the influence of "legal highs" during a domestic conflict*. [Poster]. 50th Annual Meeting of The International Association of Forensic Toxicologists (TIAFT), Hamamatsu (Japan), 2012.
- 1) **Alvarez JC**, **Carlier J**, Etting I, and Charlier P. *Les cheveux au service de l'Histoire... Ou comment identifier ce qu'ingèrent les chamanes ?* [Oral presentation]. 18th Annual Meeting of the *Société Française de Toxicologie Analytique* (SFTA), Antibes Juan-les pins (France), 2010.

Technical skills

Analytical instrument experience

LC-HRMS/MS: 1260 LC System (Agilent)-Q Exactive Plus (Thermo Scientific); UltiMate 3000 (Dionex)-Q Exactive (Thermo Scientific); LC-20ADXR HPLC (Shimadzu)-TripleTOF 5600⁺ (SCIEX)

LC-MS/MS: LCMS-8050 (Shimadzu); ACQUITY UPLC-ACQUITY TQD (Waters); Accela LC Systems-TSQ Vantage (Thermo Scientific); 1260 LC System (Agilent)-TSQ Endura (Thermo Scientific); Accela LC Systems-LCQ (Thermo Scientific)

LC-PDA-MS: ACQUITY UPLC-PDA ACQUITY UPLC-ACQUITY SQD (Waters)

GC-MS: Trace GC-PolarisQ (Thermo Scientific)

LOCI chemiluminescence: Dimension EXL with LM (Siemens)

	<p>Software experience LC(GC)-MS data processing: Xcalibur (Thermo Scientific); TraceFinder (Thermo Scientific); Analyst (SCIEX); LabSolutions (Shimadzu); MassLynx (Waters); Empower Pro 2 (Waters); Library Manager (Thermo Scientific) Metabolite identification: MetaSite (Molecular Discovery Ltd.); Compound Discoverer (Thermo Scientific); MetabolitePilot (SCIEX) LIS: LABDAQ (CompuGroup Medical); Marmotte (LATLUMTOX)</p>
Reviewer activity	<p>Analytical and Bioanalytical Chemistry, Analytical Methods, <i>Annali dell'Istituto Superiore di Sanità</i>, Biomedical Research, Current Neuropharmacology, Drug and Alcohol Dependence, Drug Testing and Analysis, Forensic Science International, Frontiers in Chemistry, Frontiers in Psychiatry, Frontiers in Veterinary Science, Journal of Agriculture and Food Chemistry, Journal of Analytical Toxicology, Journal of Pharmaceutical and Biomedical Analysis, Phytochemical Analysis, Rapid Communications in Mass Spectrometry, RSC Advances, Veterinary Record, and WIREs Forensic Science</p>
Membership	
2013 – present	Full member of The International Association of Forensic Toxicologists (TIAFT)
2013 – present	Young scientist member of the Société Française de Toxicologie Analytique (SFTA)
2013 – present	Full member of the Society Of Forensic Toxicologists (SOFT)

I hereby authorize the recipient of this document to use and process my personal details in compliance with the GDPR n. 679/2016 and with the Italian Legislative Decree no. 196 dated 30/06/2003, as modified by the legislative decree n. 101 del 2018.

Autorizzo al trattamento dei miei dati secondo il Regolamento europeo (cd. "GDPR") n. 679/2016, e secondo il D.Lgs. n. 196/2003, così come modificato dal D.Lgs. n. 101 del 2018.

Date, 6 November 2020

Signature

